This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Anti-CCR4 Antibody (Tizona)

Tizona Therapeutics, Inc.

Drug Names(s): Anti-CCR4 Antibody

Description: Tizona’s anti-CCR4 antibody selectively depletes Tregs and prevents them from migrating into the tumor microenvironment.

Deal Structure: Tizona and Ligand
In February 2016, Ligand Pharmaceuticals entered into a worldwide license agreement with Tizona Therapeutics. Under the license, Tizona will use the OmniRat, OmniMouse and OmniFlic platforms to generate fully human mono- and bispecific antibodies. Ligand will be eligible to receive annual platform access payments as well as patent filing fees, clinical milestone payments and royalties for each successful OmniAb antibody. Tizona will be responsible for all costs related to the program.

Anti-CCR4 Antibody (Tizona) News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug